Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.

ABSTRACT:

Background

Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment.

Objectives

To examine whole and segmented gray, white, thalamic, and corpus callosum volume loss in stable patients receiving natalizumab for 2-5 years.

Methods

This was a retrospective study of 20 patients undergoing treatment with natalizumab for 24-68 months. Whole brain volume loss was determined with SIENA. Gray and white matter segmentation was done using FAST. Thalamic and corpus callosum volumes were determined using Freesurfer. T1 relaxation values of chronic hypointense lesions (black holes) were determined using a quantita

SUBMITTER: Koskimaki F 

PROVIDER: S-EPMC6303064 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature